Brief: Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer
26/09/2024 12:07
Sept 26 (Reuters) - Pasithea Therapeutics Corp KTTA.O :
* PASITHEA THERAPEUTICS ANNOUNCES POSITIVE INITIAL SAFETY,
TOLERABILITY, PHARMACOKINETIC (PK), AND PRELIMINARY EFFICACY
DATA FROM ITS PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED
CANCER
* PASITHEA THERAPEUTICS CORP - PATIENT WITH STAGE 3 COLON
CANCER
ACHIEVES PROLONGED STABLE DISEASE
* PASITHEA THERAPEUTICS CORP - NO TREATMENT-RELATED ADVERSE
EVENTS
OR DOSE-LIMITING TOXICITIES OBSERVED
Source text for Eikon: ID:nGNXb1G6X
Further company coverage: KTTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement